Skip to content
AnalystLens

Exelixis 8-K Report, Financial Results (Jan 8, 2024)

Reports
Earnings & Results·Leadership Changes·Financial Events+2
Filing Date
Filed January 8, 2024
Period End
January 2, 2024
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Leadership change8-K · May ’22May ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 8-K filed January 8, 2024. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. (Nasdaq: EXEL) filed this Form 8-K on January 8, 2024 to report preliminary, unaudited financial results for the fiscal year ended December 29, 2023, provide fiscal 2024 guidance, and disclose several corporate actions.

Preliminary total revenues were approximately $1,830 milliona and net product revenues approximately $1,630 million for 2023, with R&D expenses of approximately $1,045 million and SG&A of approximately $545 million. For 2024, the company guided to total revenues of $1,825 million to $1,925 million, net product revenues of $1,650 million to $1,750 million, R&D expenses of $925 million to $975 million, and SG&A expenses of $425 million to $475 million. The audited results are scheduled for release on February 6, 2024, and the filing states the audit is ongoing and could change the preliminary figures.

Exelixis's Board authorized a restructuring plan on January 5, 2024 to reduce its workforce by approximately 175 employees, or 13% of year-end 2023 headcount, and to reduce real estate commitments and terminate certain licensing partnerships. The company estimates aggregate charges of approximately $25 millionb, of which $13.5 million relates to the workforce reduction, substantially recognized in the first quarter of 2024. The Board also authorized up to $450 million in share repurchases during 2024, following the completion of $550 million in repurchases in 2023 that retired 26.2 million shares, or 8% of shares outstanding.

Governance changes include the expansion of the Board to 13 members and the appointment of Mary C. Beckerle, Ph.D. and S. Gail Eckhardt, M.D. as directors.

Director Alan M. Garber, M.D., Ph.D. will not stand for re-election at the 2024 annual meeting. The filing also outlines 2024 milestones, including the ASCO GU presentation of CONTACT-02 data, a pending ruling in the ANDA litigation with MSN Pharmaceuticals expected in the first half of 2024, and planned IND filings for several pipeline programs.

Key Highlights

  1. Preliminary 2023 net product revenues of approximately $1,630 million and total revenues of approximately $1,830 million, subject to audit and change.
  2. 2024 guidance: total revenues of $1,825 million to $1,925 million and net product revenues of $1,650 million to $1,750 million.
  3. 2024 R&D expense guidance of $925 million to $975 million, down from preliminary 2023 R&D expenses of approximately $1,045 million; SG&A guidance of $425 million to $475 million versus approximately $545 million in 2023.
  4. Restructuring plan authorized January 5, 2024: approximately 175 employees (13% of headcount) affected, with estimated aggregate charges of approximately $25 million, $13.5 million of which relates to workforce reduction.
  5. New share repurchase authorization of up to $450 million for 2024, following $550 million of repurchases in 2023 (26.2 million shares, 8% of shares outstanding).
  6. Board expanded to 13 members with Mary C. Beckerle, Ph.D. and S. Gail Eckhardt, M.D. appointed; Alan M. Garber, M.D., Ph.D. will not stand for re-election in 2024.
  7. Audited FY2023 results to be reported February 6, 2024; MSN Pharmaceuticals ANDA ruling expected in the first half of 2024.

Frequently Asked Questions

  1. Are the 2023 financial results final?

    No. The figures are preliminary and unaudited. The filing states the audit is ongoing and could result in changes, and Exelixis plans to report audited results on February 6, 2024.

  2. What is the 2024 revenue outlook?

    Exelixis guided to total revenues of $1,825 million to $1,925 million and net product revenues of $1,650 million to $1,750 million for fiscal year 2024. The net product guidance includes a 2.2% U.S. wholesale acquisition cost increase for CABOMETYX and COMETRIQ effective January 1, 2024.

  3. How much will the restructuring cost and what does it involve?

    The company estimates aggregate charges of approximately $25 million, of which $13.5 million relates to workforce reduction. The plan eliminates about 175 employees (13% of headcount), reduces real estate commitments, and terminates certain licensing partnerships, with costs substantially recognized in the first quarter of 2024.

  4. What capital return activity is planned?

    The Board authorized repurchases of up to $450 million of common stock during 2024. Repurchases may be made through open market purchases, block trades, accelerated share repurchases, exchange transactions, or combinations thereof, depending on capital needs, alternative investments, market price, and general market conditions.

  5. What pipeline and litigation milestones are expected in 2024?

    Exelixis expects to present detailed CONTACT-02 data at the ASCO 2024 Genitourinary Cancers Symposium on January 25, 2024, and anticipates the next overall survival analysis in 2024. It expects a ruling in the MSN Pharmaceuticals ANDA litigation in the first half of 2024 and plans IND filings for XB010 in the first half of 2024 and for XB628 and XL495 in the second half of 2024 if preclinical data remain supportive.